Histopathological features of squamous cell carcinoma of lung neoadjuvant immunotherapy focusing on responses

• Published in: Zhonghua bing li xue za zhi Vol. 50; no. 5; p. 453
• Main Authors: Wei, J C, Yuan, P, Ling, Y, Li, L, Guo, C Y, Guo, L, Xue, L Y, Ying, J M
• Format: Journal Article
• Language: Chinese
• Published: China 08-05-2021
• Subjects: Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Humans; Immunotherapy; Lung; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Neoadjuvant Therapy
• ISSN: 0529-5807
• DOI: 10.3760/cma.j.cn112151-20200829-00671

To analyze the pathologic features of responses to neoadjuvant immunotherapy of squamous cell carcinoma (SCC) of the lung.
The study included 31 patients with resected lung SCC post neoadjuvant immunotherapy. All patients were recruited from the neoadjuvant anti-PD-1 (Sintilimab) phase Ⅰb clinical trial (ChiCTR-OIC-17013726). The histopathological morphology and different degrees of pathologic response to immunotherapy were evaluated basing on irPRC standard.
According to the percentage of residual viable tumor (% RVT), pathologic responses of complete pathologic response (cPR), major pathologic response (MPR) and non-MPR were noted in 19% (
=6), 29% (
=9), and 52% (
=16) of patients respectively. In addition, extensive immune activation phenomena (immune cell infiltration, including infiltration of lymphocytes, plasma cells, foamy macrophages, lymphocyte aggregation and tertiary lymphoid structures formation) and tissue repair features (giant cells, granuloma formation, proliferative fibrosis and neovascular